S. Alice Long
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
150
Citations
9,075
Est. group size
—
Recurring co-author estimate
Active years
34
Publishing since 1992
S. Alice Long studies how the immune system, especially T cells, contributes to type 1 diabetes and related autoimmune conditions, and how experimental drugs (such as teplizumab, abatacept, and alefacept) change immune cell behavior in clinical trials. The work combines detailed immune cell profiling techniques (like mass cytometry and gene expression analysis) with data from clinical studies to understand why some patients respond to therapy and others do not.
Publication output has grown over the past decade, rising from about 5 papers per year in 2017-2018 to a peak of 22 in 2023, with a slight decline in the most recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Transcriptional fingerprinting of regulatory T cells: ensuring quality in cell therapy applications
Frontiers in Immunology · 2025
- Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes
Nature Communications · 2025
- Longitudinally stable T cell function and innate immune activation distinguish healthy adult immunotypes
Science Translational Medicine · 2025
- Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes
Journal of Clinical Investigation · 2025
- Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes
The Journal of Immunology · 2025
- 1562-P: Helios+CD8 T Memory Cells, Enriched in Islet-Specific Cells of T1D Fast Progressors, Express Low Levels of CD2 and Inflammatory Cytokines
Diabetes · 2025
- Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes
Journal of Clinical Investigation · 2024
- Abatacept increases T cell exhaustion in early RA individuals who carry HLA risk alleles
Frontiers in Immunology · 2024
- Interconnected lineage trajectories link conventional and natural killer (NK)-like exhausted CD8+ T cells beneficial in type 1 diabetes
Communications Biology · 2024
- Impact on in-depth immunophenotyping of delay to peripheral blood processing
Clinical & Experimental Immunology · 2024
- 42-parameter mass cytometry panel to assess cellular and functional phenotypes of leukocytes in bronchoalveolar lavage of Rhesus macaque
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial
Diabetes Care · 2023
- A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab
Diabetologia · 2023
- Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes
JCI Insight · 2023
- Shifts in isoform usage underlie transcriptional differences in regulatory T cells in type 1 diabetes
Communications Biology · 2023
- Communications Medicine×14
- Diabetes×8
- JCI Insight×6
- The Journal of Immunology×6
- bioRxiv (Cold Spring Harbor Laboratory)×6
- Jon D. Piganelli
Biochemistry, Genetics and Molecular Biology · Indiana University
- Jamie L. Felton
Biochemistry, Genetics and Molecular Biology · Indiana University
- Emily K. Sims
Biochemistry, Genetics and Molecular Biology · Indiana University
- William Hagopian
Biochemistry, Genetics and Molecular Biology · Indiana University
- Heba M. Ismail
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile